Fulcrum Pharma, a global drug development consultancy, has recruited Barry
Knight as its chief financial officer. He will take up the position immediately.
Knight was previously finance and administrative director of KeyMed, a
medical products provider, and qualified with Ernst & Young. Prior to that,
he was CFO of biotechnology company Trigen Ltd and Trigen Holdings, where he
gained merger and acquisition experience.
Graham Cook, chairman of Fulcrum Pharma, said: ‘Barry has a distinguished
career in finance and will bring substantial healthcare finance experience to
the management team and board of Fulcrum Pharma.’
Knight replaces Geoffrey Smith, who has held the top finance spot for almost
ten years and will stay until the end of June following a handover period.
Smith, who qualified with KPMG and specialised in corporate tax at Robson
Rhodes, has played a key role in listing the company on AIM. He worked on two
acquisitions and held the interim vice presidency of the US business while at
the company. Smith started his own tax practice in 1987 which he continues to
Frank Armstrong, chief executive of Fulcrum Pharma, said: ‘With the new
management team in place he [Smith] feels it is the right time to step down as
Fulcrum Pharma moves forward to the next stage of its growth and development.’
Does Darwin's theory apply to taxation? Colin ponders...
The EC has been instructed to draft a European Union (EU) directive authorising an EU financial transaction tax, which would apply to ten of the EU’s 28 member states
Accountancy Age Jobs is delighted to announce the launch of a brand new look website for finance and accountancy professionals
The UK gender pay gap will not close until 2069 unless action is taken to tackle it now, according to new research by Deloitte